| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1001520525 |
| P356 | DOI | 10.1007/S10549-012-2158-6 |
| P698 | PubMed publication ID | 22791366 |
| P5875 | ResearchGate publication ID | 229082383 |
| P2093 | author name string | Soley Bayraktar | |
| Stefan Glück | |||
| P2860 | cites work | Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer | Q37844487 |
| Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition | Q39408501 | ||
| Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. | Q39971672 | ||
| How basal are triple-negative breast cancers? | Q40105023 | ||
| ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models | Q40138516 | ||
| BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance | Q40287564 | ||
| Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer | Q42450903 | ||
| Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype | Q42481495 | ||
| DNA repair signature is associated with anthracycline response in triple negative breast cancer patients | Q43003912 | ||
| A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer | Q43074624 | ||
| Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy | Q43222794 | ||
| Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations | Q43520691 | ||
| Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers | Q44335691 | ||
| Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer | Q45386947 | ||
| High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases. | Q46392244 | ||
| Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update | Q46838391 | ||
| Understanding the functions of BRCA1 in the DNA-damage response. | Q47800867 | ||
| Eleven years of experience with extracorporeal cardiopulmonary resuscitation for paediatric patients with in-hospital cardiac arrest. | Q50969578 | ||
| Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. | Q51754043 | ||
| Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. | Q54645721 | ||
| Surveillance for familial breast cancer: Differences in outcome according toBRCA mutation status | Q57266701 | ||
| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 | ||
| 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance | Q24599364 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2 | Q28257035 | ||
| Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer | Q28372484 | ||
| Characterization of BRCA1 and BRCA2 mutations in a large United States sample | Q28383993 | ||
| DNA repair pathways as targets for cancer therapy | Q29615572 | ||
| Hallmarks of 'BRCAness' in sporadic cancers | Q29618825 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 | ||
| Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. | Q30439093 | ||
| Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. | Q30714274 | ||
| Survival in hereditary breast cancer associated with germline mutations of BRCA2. | Q33179111 | ||
| Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy | Q33202360 | ||
| Iniparib plus chemotherapy in metastatic triple-negative breast cancer | Q33393514 | ||
| The prevalence of BRCA1 mutations among young women with triple-negative breast cancer | Q33419708 | ||
| Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers | Q33476082 | ||
| Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation | Q33558779 | ||
| A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors | Q33575946 | ||
| The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers | Q33962070 | ||
| BRCA2 mutations and triple-negative breast cancer | Q34293001 | ||
| BRCA1 and BRCA2: 1994 and beyond | Q34345297 | ||
| Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. | Q34477787 | ||
| Secondary mutations of BRCA1/2 and drug resistance | Q34983549 | ||
| A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas | Q35836463 | ||
| The role of BRCA1 in the cellular response to chemotherapy | Q35952250 | ||
| The role of the BRCA1 tumor suppressor in DNA double-strand break repair | Q36299256 | ||
| Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience | Q36920416 | ||
| A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair | Q37203855 | ||
| BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells | Q37355031 | ||
| Pathology of hereditary breast cancer | Q37740949 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| systemic therapy | Q1929812 | ||
| P304 | page(s) | 355-366 | |
| P577 | publication date | 2012-07-12 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Systemic therapy options in BRCA mutation-associated breast cancer | |
| P478 | volume | 135 |
| Q34946808 | A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer |
| Q39262474 | Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma |
| Q33894431 | BRCA1 and BRCA2 mutations and treatment strategies for breast cancer |
| Q38068925 | Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays |
| Q38389226 | Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. |
| Q38633504 | Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions |
| Q26739366 | Cytotoxic and targeted therapy for hereditary cancers |
| Q41696212 | Evaluation of psychosocial aspects in participants of cancer genetic counseling |
| Q28542563 | Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers |
| Q48005561 | Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant |
| Q26851765 | Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition |
| Q55518023 | Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. |
| Q37047682 | Predictive imaging of chemotherapeutic response in a transgenic mouse model of pancreatic cancer |
| Q35977371 | Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers |
| Q38294122 | Skin cancer risk in BRCA1/2 mutation carriers |
| Q34113473 | Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy |
| Q48588785 | Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer |
| Q38806371 | Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes |
| Q37488137 | The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma |
| Q47097677 | The role of BRCA status on prognosis in patients with triple-negative breast cancer |
| Q47159549 | Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform. |
| Q35647617 | Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways |
| Q36568348 | [(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer |
Search more.